The Global Candidiasis Market Is Projected To Driven By Rising Prevalence Of HIV/AIDS


Candidiasis, commonly known as thrush, is a fungal infection caused by any type of Candida, where Candida albicans is the most common. It can infect the mouth (oral thrush), esophagus (esophageal candidiasis), skin, and vagina (vulvovaginal candidiasis). Candidiasis infections are becoming increasingly common, especially among those with weakened immune system such as HIV/AIDS patients or people undergoing cancer treatment. Symptoms of oral thrush include white patches on the tongue or inside of the cheeks and soreness/bleeding of the mouth. Management of oral candidiasis infections mostly involves topical or oral antifungal medication.

The global candidiasis market is estimated to be valued at US$ 1134.49 Bn in 2024 and is expected to exhibit a CAGR of 8.8% over the forecast period 2024 to 2031, as highlighted in a new report published by Coherent Market Insights.

Market key trends:
One of the key trends in the candidiasis market is the rising prevalence of HIV/AIDS globally. According to UNAIDS, around 37.7 million people were living with HIV at the end of 2020 and approximately 680,000 people died from AIDS-related illnesses worldwide during 2020. Since Candida infections are more common and potentially life-threatening in people with weakened immune systems such as HIV patients, the increasing prevalence of HIV/AIDS is expected to significantly drive the growth of the candidiasis market during the forecast period. Another major trend is the development of novel antifungal agents with improved efficacy and reduced toxicity. Many pharmaceutical companies are currently conducting clinical trials to develop antifungal drugs that are safer and more effective in treating Candida infections, especially in HIV patients.

Porter’s Analysis
Threat of new entrants: The candidiasis market has moderate threat from new entrants due to presence of established brands and requirement of high R&D investments for drug development.
Bargaining power of buyers: The bargaining power of buyers is moderate due to availability of generic drugs.
Bargaining power of suppliers: Suppliers have low bargaining power due to presence of many players in the market.
Threat of new substitutes: Threat from substitutes is low as candidiasis has limited treatment options.
Competitive rivalry: The competitive rivalry is high among key players to gain major market share.

Key Takeaways
The Global Candidiasis Market Growth is expected to witness high. The global candidiasis market is estimated to be valued at US$ 1134.49 Bn in 2024 and is expected to exhibit a CAGR of 8.8% over the forecast period 2024 to 2031.

Regional analysis
North America is expected to hold major share in the global candidiasis market due to growing candida infections and rising healthcare expenditure. Europe is likely to exhibit significant growth due to rising awareness about fungal infections treatment. Asia Pacific region is anticipated to witness fastest growth owing to increasing patient pool and improving healthcare infrastructure.

Key players operating in the candidiasis market are Basilea Pharmaceutica Ltd, Astellas Pharma Inc., SCYNEXIS, Inc., NovaDigm Therapeutics, Mycovia Pharmaceuticals, Inc., Pfizer Inc, and Viatris Inc., among others. The key players are focusing on new product launches and adoption of inorganic growth strategies like mergers and acquisitions for market expansion.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it